Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer (FEVEX)

Fulvestrant Followed by Everolimus Plus Exemestane vs Examestane and Everolimus Followed by Fulvestrant in Postmenopausal Women With HR+ and HER2- Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) Previously Treated With NSAI

This is a multi-center, randomized, open-label, parallel group study designed to evaluate efficacy and safety of fulvestrant followed, at progression, by examestane and everolimus versus examestane and everolimus followed, at progression, by fulvestrant in postmenopausal women with HR+ and HER2- LABC or MBC whose disease has progressed to NSAI in the adjuvant or metastatic setting.

Study Overview

• Status: Unknown
• Conditions: Breast Cancer; Metastatic Breast Cancer; Hormone Receptor Positive Tumor; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; Locally Advanced Malignant Neoplasm
• Intervention / Treatment: Drug: Everolimus; Drug: Exemestane; Drug: Fulvestrant

Detailed Description

In this study everolimus will be administered in combination with exemestane, which is an irreversible steroidal aromatase inactivator that has demonstrated efficacy in the treatment of postmenopausal patients with ABC. Exemestane is indicated for adjuvant treatment of postmenopausal women with HR+ EBC who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy. It is also indicated for the treatment of ABC in postmenopausal women whose disease has progressed following tamoxifen therapy (in the USA) or following antiestrogen therapy (in Europe). In 2011, the BOLERO-2 trial reported (5; 33) a significant benefit for HR+ HER2- postmenopausal pretreated women in the ABC setting by combining everolimus with exemestane. In this randomized, double-blind, placebo-controlled trial a statistically significant improvement in PFS by adding everolimus to exemestane versus exemestane alone was reported. Adding everolimus determined a 2.4-fold prolongation in PFS from 3.2 up to 7.4 months and so lowered the risk of cancer progression by 56% for these women. These findings were confirmed by an independent assessment (4.1 vs. 11.0 months, risk reduction: 64%). The QoL data shows positive trend in the everolimus plus exemestane treatment arm.

• Study Type: Interventional
• Enrollment (Anticipated): 745
• Phase: Phase 3

Contacts and Locations

Study Locations

• Italy
  • Asti, Italy
    • Recruiting
    • ASL19 - Ospedale Cardinal Massaia
  • Bari, Italy
    • Not yet recruiting
    • Azienda Ospedaliera Policlinico Di Bari
  • Bari, Italy
    • Not yet recruiting
    • Istituto Tumori Giovanni Paolo II
  • Benevento, Italy
    • Not yet recruiting
    • Azienda Ospedaliera "G. Rummo"
  • Benevento, Italy
    • Not yet recruiting
    • Ospedale Fatebenefratelli 'Sacro Cuore di Gesù' di Benevento
  • Bergamo, Italy
    • Recruiting
    • A.O. Ospedale Papa Giovanni XXIII
  • Brindisi, Italy
    • Recruiting
    • Presidio Ospedaliero Antonio Perrino
  • Cagliari, Italy
    • Not yet recruiting
    • Azienda Ospedaliera - A. Businco - A.S.L. N. 8
  • Candiolo, Italy
    • Recruiting
    • Fondazione del Piemonte per l' Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.)
  • Castellaneta, Italy
    • Not yet recruiting
    • ASL di Taranto - Polo Occidentale
  • Catania, Italy
    • Recruiting
    • A.O.R.N.A.S. Garibaldi Nesima di Catania
  • Catanzaro, Italy
    • Not yet recruiting
    • Fondazione per la Ricerca e la Cura dei Tumori T. Campanella - Campus S. Venuta
  • Cuneo, Italy
    • Recruiting
    • Azienda Ospedaliera S. Croce e Carle
  • Faenza, Italy
    • Recruiting
    • Ospedale Infermi di Rimini
  • Firenze, Italy
    • Not yet recruiting
    • Azienda Ospedaliera Universitaria Careggi
  • Foggia, Italy
    • Not yet recruiting
    • Azienda Ospedaliero - Universitaria Ospedali Riuniti di Foggia
  • Genova, Italy
    • Recruiting
    • I.R.C.C.S. A.O.U San Martino - IST
  • Guastalla, Italy
    • Recruiting
    • Ospedale Civile di Guastalla
  • L'Aquila, Italy
    • Not yet recruiting
    • Ospedale Civile San Salvatore - Università degli Studi L'Aquila
  • Lanciano, Italy
    • Recruiting
    • Presidio Ospedaliero "Renzetti"
  • Lecce, Italy
    • Recruiting
    • Ospedale Vito Fazzi
  • Macerata, Italy
    • Not yet recruiting
    • Ospedale Di Macerata
  • Messina, Italy
    • Recruiting
    • AO Papardo
  • Napoli, Italy
    • Recruiting
    • AORN . Ospedali dei colli Monaldi-Cotugno
  • Napoli, Italy
    • Recruiting
    • Azienda Ospedaliera 'A. Cardarelli' (AORN)
  • Napoli, Italy
    • Recruiting
    • Azienda Ospedaliera Universitaria Federico II
  • Napoli, Italy
    • Recruiting
    • Istituto Nazionale per lo studio dei Tumori - Fondazione 'Pascale'
  • Novara, Italy
    • Recruiting
    • A.O.U. 'Maggiore della Carità'
  • Palermo, Italy
    • Recruiting
    • A.O.U.P. 'Paolo Giaccone'
  • Pisa, Italy
    • Recruiting
    • Azienda Ospedaliera S. Chiara
  • Pontedera, Italy
    • Recruiting
    • Ospedale F. Lotti
  • Ravenna, Italy
    • Recruiting
    • Ospedale di Ravenna
  • Roma, Italy
    • Recruiting
    • Campus Biomedico di Roma
  • Roma, Italy
    • Recruiting
    • Istituto Regina Elena per lo studio e la cura dei tumori - Oncologia A
  • Roma, Italy
    • Recruiting
    • Istituto Regina Elena per lo studio e la cura dei tumori - Oncologia B
  • Salerno, Italy
    • Recruiting
    • Azienda Ospedaliera 'San Giovanni di Dio e Ruggi D'Aragona'
  • San Giovanni rotondo, Italy
    • Recruiting
    • IRCCS - Istituto di Ricovero e Cura a Carattere Scientifico 'Casa Sollievo della Sofferenza'
  • Sassari, Italy
    • Not yet recruiting
    • Azienda Ospedaliera Universitaria di Sassari
  • Udine, Italy
    • Not yet recruiting
    • Azienda Ospedaliero Universitaria ´S. Maria della Misericordia´ di Udine
  • Verona, Italy
    • Recruiting
    • "Ospedale Borgo Roma Verona Sezione di Oncologia Medica"
  • Verona, Italy
    • Recruiting
    • Ospedale Sacro Cuore Don Calabria di Negrar

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Adult women (≥ 18 years of age) with LABC or MBC not amenable to curative treatment by surgery or radiotherapy, refractory to NSAI
2. Histological or cytological confirmation of ER+ BC and/or PgR+.
3. Postmenopausal women.
4. Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to randomization

5. Patients must have:

   • At least one lesion that can be accurately measured in at least one dimension ≥ 20 mm with conventional imaging techniques or ≥ 10 mm with spiral CT or MRI
   • Bone lesions: lytic or mixed (lytic + sclerotic) in the absence of measurable disease as defined above.
6. Adequate bone marrow and coagulation according RCP
7. Adequate liver function, according RCP
8. Adequate renal function, according RCP
9. ECOG Performance Status ≤ 2
10. Written informed consent

Exclusion Criteria:

1. HER2-overexpressing patients by local laboratory testing (IHC3+ staining or in situ hybridization positive).
2. Patients who received chemotherapy for MBC
3. Patients who received more than one NSAI treatment for LABC or MBC
4. Pre-menopausal, pregnant, lactating women.
5. Known hypersensitivity to mTOR inhibitors
6. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose galactose malabsorption.
7. Radiotherapy within four weeks prior to enrollment
8. Currently receiving hormone replacement therapy, unless discontinued prior to enrollment.
9. Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use, at the time of study entry except in some cases
10. Patients with symptomatic visceral disease in need of urgent disease control
11. Symptomatic brain or other CNS metastases.
12. Patients with a known history of HIV seropositivity.
13. Active, bleeding diathesis, or on oral anti-vitamin K medication (except cases).

14. Any severe and / or uncontrolled medical conditions such as:

    • Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months prior to enrollment, serious uncontrolled cardiac arrhythmia
    • Uncontrolled diabetes as defined by fasting serum glucose > 1.5 × ULN
    • Acute and chronic, active infectious disorders
    • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of the study treatments (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
    • Inability to swallow oral medications
    • Significant symptomatic deterioration of lung function.

15. Hepatic-related exclusion criteria:

    • History of liver disease, such as cirrhosis or chronic active hepatitis B and C.
    • Presence of Hepatitis B surface antigen (HbsAg) and/or of Hepatitis B Virus - Deoxyribonucleic acid (HBV-DNA)
    • Presence of anti-HCV and/or HCV-RNA-PCR
    • History of, or current alcohol misuse/abuse within the past 12 months
    • Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A within the last 5 days prior to enrollment.
    • History of non-compliance to medical regimens.
    • Patients unwilling to or unable to comply with the protocol
16. Patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A
17. History of non-compliance to medical regimens.
18. Patients unwilling to or unable to comply with the protocol.

Screening for hepatitis B

Prior to enrollment, peculiar patients should be tested for hepatitis B viral load and serologic markers, that is, HBV-DNA, HBsAg, HBsAb, and HBcAb:

Screening for hepatitis C Patients with any of the following risk factors for hepatitis C should be tested

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ARM 1; Everolimus plus Exemestane -> progression disease (PD) -> fulvestrant (ARM 1)	Drug: Everolimus; 10 mg daily tablets; Other Names: Afinitor; Drug: Exemestane; 25 mg daily tablets; Other Names: Aromasin; Drug: Fulvestrant; 500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter; Other Names: Faslodex
Experimental: ARM 2; Fulvestrant -> progression disease (PD) -> everolimus plus exemestane (ARM 2)	Drug: Everolimus; 10 mg daily tablets; Other Names: Afinitor; Drug: Exemestane; 25 mg daily tablets; Other Names: Aromasin; Drug: Fulvestrant; 500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter; Other Names: Faslodex

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free survival (PFS1)	The number of events required for the other primary endpoint (PFS1), and the expected time needed to achieve it are derived from previous calculations. Assuming an average accrual rate of 31 pts/month (677pts/22 months), a median PFS1 of 6 months in the Fulvestrant arm (control), a Hazard ratio of 0.70 (implying that a median PFS1 of 8,6 months is expected in the experimental arm, a 2-sided significance level of 0.025 and power of 0.90, 391 events are required for PFS1, that will be achieved in about 22 months (East 6 software).	Time elapsed from randomization to progression or death for any cause whichever occurred first assessed up to 30 months
Total Progression-free survival (PFST)	Overall study size is driven by the endpoint less frequent (PFST). Sample size is planned to identify a Hazard ratio of 0.75, assuming an overall study duration of 36 months, an accrual duration of 24 months, a 2-sided significance level of 0.025 and power of 0.80. Assuming a median PFST of 12 months in the Fulvestrant arm (control), the expected PFST in the experimental arm will be equal to 16 months and 677 subjects need to be enrolled (East 6 software) with an average accrual rate equal to 30.8 patients/month (11 months per year have been considered).	Time elapsed from randomization to progression or death for any cause whichever occurred first assessed up to 30 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Response Rate	Objective Response Rate (ORR), the Clinical Benefit, the overall survival, and the safety profile and the QOLof of the sequence of fulvestrant followed, at progression by exemestane and everolimus versus the sequence of examestane and everolimus followed, at progression, by fulvestrant in postmenopausal women with HR + and HER2- LABC or MBC previously treated with NSAI in the adjuvant or metastatic setting.	Time elapsed from randomization to progression or death for any cause whichever occurred first assessed up to 30 months
Clinical Benefit Rate	Objective Response Rate (ORR), the Clinical Benefit, the overall survival, and the safety profile and the QOLof of the sequence of fulvestrant followed, at progression by exemestane and everolimus versus the sequence of examestane and everolimus followed, at progression, by fulvestrant in postmenopausal women with HR + and HER2- LABC or MBC previously treated with NSAI in the adjuvant or metastatic setting.	Time elapsed from randomization to progression or death for any cause whichever occurred first assessed up to 30 months
Overall Survival	Objective Response Rate (ORR), the Clinical Benefit, the overall survival, and the safety profile and the QOLof of the sequence of fulvestrant followed, at progression by exemestane and everolimus versus the sequence of examestane and everolimus followed, at progression, by fulvestrant in postmenopausal women with HR + and HER2- LABC or MBC previously treated with NSAI in the adjuvant or metastatic setting.	Time elapsed from randomization to progression or death for any cause whichever occurred first assessed up to 30 months
Safety - 5D5L questionnaire	The overall observation period will be divided into three mutually exclusive segments per treatment phase: pre-treatment period: from day of patient's informed consent to the day before first dose of study medication (phase 1) on-treatment period: from day of first dose of study medication to 30 days (minimum washout) after last dose of study medication (phase 2) or first dose of second phase treatment after cross-over; post-treatment period: starting at day 31 after last dose of study medication (phase 2)	up to 31 days since last treatment

Collaborators and Investigators

• Sponsor: Consorzio Oncotech
• Collaborators: Clinical Research Technology S.r.l.
• Investigators: Principal Investigator: Sabino De Placido, MD, Dipartimento di Medicina Clinica e Chirurgia Oncologia Università degli Studi di Napoli "Federico II"

Study record dates

Study Major Dates

• Study Start: December 1, 2015
• Primary Completion (Anticipated): January 1, 2018
• Study Completion (Anticipated): January 1, 2019

Study Registration Dates

• First Submitted: January 26, 2015
• First Submitted That Met QC Criteria: March 26, 2015
• First Posted (Estimate): March 31, 2015

Study Record Updates

• Last Update Posted (Estimate): June 15, 2016
• Last Update Submitted That Met QC Criteria: June 14, 2016
• Last Verified: June 1, 2016

More Information

Terms related to this study

• Keywords: Breast cancer; Metastatic; everolimus; Locally Advanced; fulvestrant; exemestane; hormone receptor positive (HR+); HER2Negative
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms by Site; Breast Diseases; Neoplasms; Breast Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Hormone Antagonists; Aromatase Inhibitors; Steroid Synthesis Inhibitors; Estrogen Antagonists; Estrogen Receptor Antagonists; Fulvestrant; Everolimus; Exemestane
• Other Study ID Numbers: GIM16-FEVEX; 2014-004035-38 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No